Westfield Capital Management’s Axsome Therapeutics AXSM Stock Holding History

Westfield Capital Management’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$35.5M	Buy	+145,145	New	+$31.5M	0.12%	192

Other funds holding AXSM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Westfield Capital Management's AXSM Position: Q2 2026 in Review

Westfield Capital Management opened a new position in Axsome Therapeutics (AXSM) in Q2 2026: 145,145 shares worth $35.5M. The stake represents 0.12% of the portfolio and ranks #192 among its holdings.

504 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

Westfield Capital Management held 145,145 shares of Axsome Therapeutics worth $35.5M as of Q2 2026.
Axsome Therapeutics was a new Westfield Capital Management position in Q2 2026.
Axsome Therapeutics made up 0.12% of Westfield Capital Management's portfolio in Q2 2026, its #192 holding.
504 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Westfield Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.